Metformin + Sitagliptin

Concise Prescribing Info
Type 2 DM.
Dosage/Direction for Use
Adult : PO Each tab contains sitagliptin and metformin (conventional: 50 mg/500 mg, 50 mg/1000 mg; extended-release: 50 mg/500 mg, 50 mg/1000 mg, 100 mg/1000 mg): Patient not currently treated w/ metformin: Initial: 100 mg/1000 mg/day. Patient currently treated w/ metformin: Initial: Sitagliptin 100 mg and current daily metformin dose. Doses are given in 2 divided doses (conventional) or once daily (extended-release). Max: Sitagliptin 100 mg/metformin 2000 mg/day.
Dosage Details
Type 2 diabetes mellitus
Adult: Each tab contains sitagliptin and metformin (conventional: 50 mg/500 mg, 50 mg/1000 mg; extended-release: 50 mg/500 mg, 50 mg/1000 mg, 100 mg/1000 mg): Patients not currently treated w/ metformin: Initially, 100 mg/1000 mg daily. Patients currently treated w/ metformin: Initially, sitagliptin 100 mg and current daily metformin dose. Patients currently treated w/ metformin 1700 mg daily may receive 100 mg/2000 mg daily. Total daily doses are given in 2 divided doses (conventional) or once daily (extended-release). Max: Sitagliptin 100 mg/ and metformin 2000 mg daily.
Renal Impairment
Severe (GFR <30 mL/min): Contraindicated.
Hepatic Impairment
Should be taken with food.
Diabetic pre-coma, acute or chronic metabolic acidosis (e.g. diabetic ketoacidosis, lactic acidosis), alcoholism or acute alcohol intoxication, acute or chronic disease that may cause hypoxia (e.g. cardiac or resp failure, recent MI, shock), conditions which may alter renal function (e.g. severe infection, dehydration). Intravascular admin of iodinated contrast agents. Hepatic and severe renal impairment (GFR <30 mL/min). Lactation.
Special Precautions
Patient w/ CHF and those who are exposed to stress (e.g. infection, fever, trauma, surgery). Not intended for the treatment of diabetic ketoacidosis or type 1 DM. Renal impairment (GFR 30-45 mL/min). Pregnancy.
Adverse Reactions
Significant: Bullous pemphigoid, severe arthralgia, hypoglycaemia. Rarely, serious hypersensitivity reactions (e.g. anaphylaxis, angioedema, exfoliative skin conditions including Stevens-Johnson syndrome).
Nervous: Headache, somnolence, dizziness.
GI: Diarrhoea, nausea, abdominal pain, vomiting, constipation.
Resp: Upper resp tract infection, nasopharyngitis.
Hepatic: Increased liver enzymes.
Genitourinary: Renal failure.
Musculoskeletal: Back pain.
Dermatologic: Rash, pruritus, urticaria.
Potentially Fatal: Lactic acidosis, acute pancreatitis (including haemorrhagic or necrotising pancreatitis).
Patient Counseling Information
This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.
Monitor glycosylated Hb (HbA1c), serum glucose, hepatic and renal function, haematologic parameters prior to initiation of therapy and periodically thereafter.
Drug Interactions
Sitagliptin may increase risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin. Increased risk of lactic acidosis w/ topiramate or other carbonic anhydrase inhibitors (e.g. zonisamide, acetazolamide, dichlorphenamide), NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, diuretics. Concomitant cationic drugs that interfere w/ renal tubular transport systems (e.g. ranolazine, vandetanib, dolutegravir, cimetidine) may increase metformin levels. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, OCs, sympathomimetics, phenytoin, niacin, Ca channel blockers and isoniazid may produce hyperglycaemia which may lead to loss of glycaemic control. Metformin may impair vit B12 absorption.
Potentially Fatal: Intravascular admin of iodinated contrast agents may cause renal dysfunction, leading to metformin-induced lactic acidosis.
Food Interaction
Food decreases the extent and slightly delays absorption of metformin. Alcohol may potentiate the effect of metformin on lactate metabolism.
Description: Metformin is a biguanide antidiabetic agent that reduces hepatic glucose production by decreasing gluconeogenesis and glycogenolysis, decreases intestinal absorption of glucose and enhances insulin sensitivity by increasing peripheral utilisation and uptake of glucose. Sitagliptin inhibits dipeptidylpeptidase-4 (DPP-4), an enzyme that inactivates incretin hormones. Inhibition of DPP-4 results in an increase in the levels of incretin hormones [e.g. glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] which regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic β-cells and decreasing glucagon secretion from pancreatic α-cells, leading to reduced hepatic glucose production.
Absorption: Metformin: Slowly and incompletely absorbed from the GI tract. Absolute bioavailability: Approx 50-60%; reduced if taken w/ food. Time to peak plasma concentration: 2-3 hr (immediate-release); 4-8 hr (extended-release). Sitagliptin: Rapidly absorbed from the GI tract. Bioavailability: Approx 87%. Time to peak plasma concentration: Approx 1-4 hr.
Distribution: Metformin: Partitions into erythrocytes; concentrates in kidney, liver, and GI tract. Crosses the placenta and enters breast milk (small amounts). Volume of distribution: 654 ±358 L. Sitagliptin: Volume of distribution: Approx 198 L. Plasma protein binding: 38%.
Metabolism: Sitagliptin: Undergoes minimal metabolism, mainly by CYP3A4 enzyme and to a lesser extent by CYP2C8 enzyme to inactive metabolites.
Excretion: Metformin: Via urine (90% as unchanged drug). Plasma elimination half-life: Approx 2-6 hr. Sitagliptin: Via urine (approx 79% as unchanged drug, 16% as metabolites) and faeces (13%). Elimination half-life: 12.4 hr.
Chemical Structure

Click on icon to see table/diagram/image

Click on icon to see table/diagram/image
Store between 20-25°C.
MIMS Class
ATC Classification
A10BD07 - metformin and sitagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by MIMS based on Metformin + Sitagliptin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in